Spruce hooks a commercial chief to prep for rare disease launch
Spruce Biosciences Inc posts Q4 2025 results with non-GAAP EPS $-8.73 on revenue $0, beats EPS and revenue estimates, secures up to $50M debt funding
- Company also reported FY 2025 results in addition to Q4 2025 figures.
- Positive FDA Type B meetings support tralesinidase alfa development ahead of the planned Q4 2026 BLA submission.
- Company projects cash runway into early 2027 following securing a new debt facility of up to $50 million.
- Spruce appointed rare-disease commercial leader Dale Hooks as chief commercial officer with an 11,000 RSU inducement award.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.